These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
137 related articles for article (PubMed ID: 26950217)
1. Pravastatin and Sarpogrelate Synergistically Ameliorate Atherosclerosis in LDLr-Knockout Mice. Park KY; Oh E; Kwak MK; Jun HS; Heo TH PLoS One; 2016; 11(3):e0150791. PubMed ID: 26950217 [TBL] [Abstract][Full Text] [Related]
2. Combination therapy with cilostazol and pravastatin improves antiatherogenic effects in low-density lipoprotein receptor knockout mice. Park KY; Heo TH Cardiovasc Ther; 2018 Dec; 36(6):e12476. PubMed ID: 30378752 [TBL] [Abstract][Full Text] [Related]
3. Critical role of TNF inhibition in combination therapy for elderly mice with atherosclerosis. Park KY; Heo TH Cardiovasc Ther; 2017 Dec; 35(6):. PubMed ID: 28643478 [TBL] [Abstract][Full Text] [Related]
4. Pravastatin attenuates interferon-gamma action via modulation of STAT1 to prevent aortic atherosclerosis in apolipoprotein E-knockout mice. Zhou XX; Gao PJ; Sun BG Clin Exp Pharmacol Physiol; 2009 Apr; 36(4):373-9. PubMed ID: 19018808 [TBL] [Abstract][Full Text] [Related]
5. Anti-atherosclerotic effects of pravastatin in brachiocephalic artery in comparison with en face aorta and aortic roots in ApoE/LDLR Kostogrys RB; Franczyk-Zarow M; Gasior-Glogowska M; Kus E; Jasztal A; Wrobel TP; Baranska M; Czyzynska-Cichon I; Drahun A; Manterys A; Chlopicki S Pharmacol Rep; 2017 Feb; 69(1):112-118. PubMed ID: 27915184 [TBL] [Abstract][Full Text] [Related]
6. Akt2/LDLr double knockout mice display impaired glucose tolerance and develop more complex atherosclerotic plaques than LDLr knockout mice. Rensing KL; de Jager SC; Stroes ES; Vos M; Twickler MT; Dallinga-Thie GM; de Vries CJ; Kuiper J; Bot I; von der Thüsen JH Cardiovasc Res; 2014 Feb; 101(2):277-87. PubMed ID: 24220638 [TBL] [Abstract][Full Text] [Related]
7. The effects of diet on occlusive coronary artery atherosclerosis and myocardial infarction in scavenger receptor class B, type 1/low-density lipoprotein receptor double knockout mice. Fuller M; Dadoo O; Serkis V; Abutouk D; MacDonald M; Dhingani N; Macri J; Igdoura SA; Trigatti BL Arterioscler Thromb Vasc Biol; 2014 Nov; 34(11):2394-403. PubMed ID: 25212235 [TBL] [Abstract][Full Text] [Related]
8. The role of heat shock protein 90 in migration and proliferation of vascular smooth muscle cells in the development of atherosclerosis. Kim J; Jang SW; Park E; Oh M; Park S; Ko J J Mol Cell Cardiol; 2014 Jul; 72():157-67. PubMed ID: 24650873 [TBL] [Abstract][Full Text] [Related]
9. Pharmacological inhibition of the chemokine receptor, CX3CR1, reduces atherosclerosis in mice. Poupel L; Boissonnas A; Hermand P; Dorgham K; Guyon E; Auvynet C; Charles FS; Lesnik P; Deterre P; Combadiere C Arterioscler Thromb Vasc Biol; 2013 Oct; 33(10):2297-305. PubMed ID: 23887641 [TBL] [Abstract][Full Text] [Related]
10. Pravastatin polarizes the phenotype of macrophages toward M2 and elevates serum cholesterol levels in apolipoprotein E knockout mice. Zhang X; Xiao S; Li Q J Int Med Res; 2018 Aug; 46(8):3365-3373. PubMed ID: 30058421 [TBL] [Abstract][Full Text] [Related]
11. TUG1 knockdown ameliorates atherosclerosis via up-regulating the expression of miR-133a target gene FGF1. Zhang L; Cheng H; Yue Y; Li S; Zhang D; He R Cardiovasc Pathol; 2018; 33():6-15. PubMed ID: 29268138 [TBL] [Abstract][Full Text] [Related]
12. 4-phenylbutyrate and valproate treatment attenuates the progression of atherosclerosis and stabilizes existing plaques. Huang A; Young TL; Dang VT; Shi Y; McAlpine CS; Werstuck GH Atherosclerosis; 2017 Nov; 266():103-112. PubMed ID: 29024862 [TBL] [Abstract][Full Text] [Related]
18. Olmesartan and pravastatin additively reduce development of atherosclerosis in APOE*3Leiden transgenic mice. van der Hoorn JW; Kleemann R; Havekes LM; Kooistra T; Princen HM; Jukema JW J Hypertens; 2007 Dec; 25(12):2454-62. PubMed ID: 17984667 [TBL] [Abstract][Full Text] [Related]
19. Hematopoietic arginase 1 deficiency results in decreased leukocytosis and increased foam cell formation but does not affect atherosclerosis. Ren B; Van Kampen E; Van Berkel TJ; Cruickshank SM; Van Eck M Atherosclerosis; 2017 Jan; 256():35-46. PubMed ID: 27998825 [TBL] [Abstract][Full Text] [Related]
20. MicroRNA 302a is a novel modulator of cholesterol homeostasis and atherosclerosis. Meiler S; Baumer Y; Toulmin E; Seng K; Boisvert WA Arterioscler Thromb Vasc Biol; 2015 Feb; 35(2):323-31. PubMed ID: 25524771 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]